ATEC

Alphatec Holdings, Inc.

Fundamental data last updated:June 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

07/30/2026

Business Summary

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.

 


VALUATION

P/E

-9.70

Market Cap ($M USD)

$1.21B

Forward P/E

4.96

PEG

0.02

PRICE TO SALES

1.54

PRICE TO BOOK

66.58

EV / EBITDA

-1313.91

5-Year Average P/E

Free Cash Flow Yield

0.57%

DCF Value

$13.71

Graham Number

N/A

Price to FCF

174.61

EV to FCF

241.26

Earnings Yield

-10.31%

FCF Yield

0.57%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.81

Next Year EPS Growth Estimate

$1.59

Next Year Revenue Growth Estimate

$149.62B

Return on Equity (ROE)

-443.09%

FREE CASH FLOW

Operating Margin

-7.17%

Debt-to-Equity

17.21

Piotroski F-Score

4

Altman Z-Score

-0.62

Return on Invested Capital (ROIC)

-10.09%

Current Ratio

1.90

Quick Ratio

1.12

Net Debt to EBITDA

-362.97

Interest Coverage

-1.34

Gross Profit margin

65.32%

FCF PER SHARE

$0.05

REVENUE PER SHARE

$5.11

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing ATEC relative to its DCF Value, with recent pricing indicating it traded below this intrinsic estimate. Despite a promising Forward P/E of 4.73, suggesting future profitability, the company’s current financial health is precarious. The negative Altman Z-score of -0.70 signals potential distress, while an earnings yield of -10.82% highlights ongoing losses. The stark contrast between the negative current earnings and the optimistic EPS estimate for next year underscores a high-risk, high-reward scenario.

AI Exposure / Tech Reliance

Operating within the Medical Devices industry, ATEC is well-positioned to leverage AI advancements in healthcare. The integration of AI can enhance precision in device functionality and patient outcomes. As the industry evolves, ATEC's adaptability to tech shifts could be a crucial differentiator.

The Bull Case

For the value or GARP investor, ATEC presents an intriguing opportunity. The Forward PEG ratio of 0.016 suggests significant undervaluation relative to expected growth. Despite a negative ROIC of -10.09%, the company's gross profit margin of 65.32% indicates strong pricing power. The Piotroski F-Score of 4, while moderate, suggests some financial stability, and the FCF Yield, though low, points to potential cash flow improvements.

The Bear Case

However, the structural risks are glaring. A staggering Price/Book ratio of 63.46 raises red flags about overvaluation. The negative EV to EBITDA and operating margin of -7.17% highlight severe profitability issues. With a Debt/Equity ratio of 17.21, the company is heavily leveraged, posing significant financial risk. The technical overextension near its 52-week high further exacerbates concerns about its current valuation.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$19.71

Institutional Ownership %

1-Year Beta

0.97

Insider Buying % (6 Mo)

Distance to 52-Week High

195.18%

Distance to 52-Week Low

13.56%

EARNINGS SURPRISE %

-2,100.00%

50-DAY SMA

$9.99

200-DAY SMA

$15.01

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.